1	Inhibition	Inhibition	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	nuclear	nuclear	_	_	_	_	_	_	_
4	factor	factor	_	_	_	_	_	_	_
5	kappaB	kappab	_	_	_	_	_	_	_
6	activation	activation	_	_	_	_	_	_	_
7	attenuates	attenuate	_	_	_	_	_	_	_
8	apoptosis	apoptosis	_	_	_	_	_	_	_
9	resistance	resistance	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	lymphoid	lymphoid	_	_	_	_	_	_	_
12	cells	cell	_	_	_	_	_	_	_
13	.	.	_	_	_	_	_	_	_

1	Death-inducing	death-inducing	_	_	_	_	_	_	_
2	ligands	ligand	_	_	_	_	_	_	_
3	(	(	_	_	_	_	_	_	_
4	DILs	DIL	_	_	_	_	_	_	_
5	)	)	_	_	_	_	_	_	_
6	such	such	_	_	_	_	_	_	_
7	as	as	_	_	_	_	_	_	_
8	tumor	tumor	_	_	_	_	_	_	_
9	necrosis	necrosis	_	_	_	_	_	_	_
10	factor	factor	_	_	_	_	_	_	_
11	alpha	alpha	_	_	_	_	_	_	_
12	(	(	_	_	_	_	_	_	_
13	TNFalpha	TNFalpha	_	_	_	_	_	_	_
14	)	)	_	_	_	_	_	_	_
15	or	or	_	_	_	_	_	_	_
16	the	the	_	_	_	_	_	_	_
17	cytotoxic	cytotoxic	_	_	_	_	_	_	_
18	drug	drug	_	_	_	_	_	_	_
19	doxorubicin	doxorubicin	_	_	_	_	_	_	_
20	have	have	_	_	_	_	_	_	_
21	been	be	_	_	_	_	_	_	_
22	shown	show	_	_	_	_	_	_	_
23	to	to	_	_	_	_	_	_	_
24	activate	activate	_	_	_	_	_	_	_
25	a	a	_	_	_	_	_	_	_
26	nuclear	nuclear	_	_	_	_	_	_	_
27	factor	factor	_	_	_	_	_	_	_
28	kappaB	kappaB	_	_	_	_	_	_	_
29	(	(	_	_	_	_	_	_	_
30	NFkappaB)-dependent	nfkappab)-dependent	_	_	_	_	_	_	_
31	program	program	_	_	_	_	_	_	_
32	that	that	_	_	_	_	_	_	_
33	may	may	_	_	_	_	_	_	_
34	rescue	rescue	_	_	_	_	_	_	_
35	cells	cell	_	_	_	_	_	_	_
36	from	from	_	_	_	_	_	_	_
37	apoptosis	apoptosis	_	_	_	_	_	_	_
38	induction	induction	_	_	_	_	_	_	_
39	.	.	_	_	_	_	_	_	_

1	We	we	_	_	_	_	_	_	_
2	demonstrate	demonstrate	_	_	_	_	_	_	_
3	here	here	_	_	_	_	_	_	_
4	that	that	_	_	_	_	_	_	_
5	TRAIL	TRAIL	_	_	_	_	_	_	_
6	(	(	_	_	_	_	_	_	_
7	TNF-related	tnf-related	_	_	_	_	_	_	_
8	apoptosis-inducing	apoptosis-inducing	_	_	_	_	_	_	_
9	ligand	ligand	_	_	_	_	_	_	_
10	)	)	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	a	a	_	_	_	_	_	_	_
13	recently	recently	_	_	_	_	_	_	_
14	identified	identify	_	_	_	_	_	_	_
15	DIL	DIL	_	_	_	_	_	_	_
16	,	,	_	_	_	_	_	_	_
17	also	also	_	_	_	_	_	_	_
18	activates	activate	_	_	_	_	_	_	_
19	NFkappaB	nfkappab	_	_	_	_	_	_	_
20	in	in	_	_	_	_	_	_	_
21	lymphoid	lymphoid	_	_	_	_	_	_	_
22	cell	cell	_	_	_	_	_	_	_
23	lines	line	_	_	_	_	_	_	_
24	in	in	_	_	_	_	_	_	_
25	a	a	_	_	_	_	_	_	_
26	kinetic	kinetic	_	_	_	_	_	_	_
27	similar	similar	_	_	_	_	_	_	_
28	to	to	_	_	_	_	_	_	_
29	TNFalpha	TNFalpha	_	_	_	_	_	_	_
30	.	.	_	_	_	_	_	_	_

1	NFkappaB	NFkappaB	_	_	_	_	_	_	_
2	activity	activity	_	_	_	_	_	_	_
3	is	be	_	_	_	_	_	_	_
4	independent	independent	_	_	_	_	_	_	_
5	from	from	_	_	_	_	_	_	_
6	FADD	FADD	_	_	_	_	_	_	_
7	,	,	_	_	_	_	_	_	_
8	caspases	caspas	_	_	_	_	_	_	_
9	,	,	_	_	_	_	_	_	_
10	and	and	_	_	_	_	_	_	_
11	apoptosis	apoptosis	_	_	_	_	_	_	_
12	induction	induction	_	_	_	_	_	_	_
13	.	.	_	_	_	_	_	_	_

1	To	to	_	_	_	_	_	_	_
2	study	study	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	influence	influence	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	NFkappaB	NFkappaB	_	_	_	_	_	_	_
7	activity	activity	_	_	_	_	_	_	_
8	on	on	_	_	_	_	_	_	_
9	apoptosis	apoptosis	_	_	_	_	_	_	_
10	mediated	mediate	_	_	_	_	_	_	_
11	by	by	_	_	_	_	_	_	_
12	TRAIL	TRAIL	_	_	_	_	_	_	_
13	,	,	_	_	_	_	_	_	_
14	CD95	CD95	_	_	_	_	_	_	_
15	,	,	_	_	_	_	_	_	_
16	TNFalpha	TNFalpha	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	or	or	_	_	_	_	_	_	_
19	doxorubicin	doxorubicin	_	_	_	_	_	_	_
20	,	,	_	_	_	_	_	_	_
21	NFkappaB	NFkappaB	_	_	_	_	_	_	_
22	activation	activation	_	_	_	_	_	_	_
23	was	be	_	_	_	_	_	_	_
24	inhibited	inhibit	_	_	_	_	_	_	_
25	using	use	_	_	_	_	_	_	_
26	the	the	_	_	_	_	_	_	_
27	proteasome	proteasome	_	_	_	_	_	_	_
28	inhibitor	inhibitor	_	_	_	_	_	_	_
29	N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal	n-acetyl-l-leucinyl-l-leucinyl-l-norleucinal	_	_	_	_	_	_	_
30	or	or	_	_	_	_	_	_	_
31	transient	transient	_	_	_	_	_	_	_
32	overexpression	overexpression	_	_	_	_	_	_	_
33	of	of	_	_	_	_	_	_	_
34	mutant	mutant	_	_	_	_	_	_	_
35	IkappaBalpha	IkappaBalpha	_	_	_	_	_	_	_
36	.	.	_	_	_	_	_	_	_

1	Sensitivity	sensitivity	_	_	_	_	_	_	_
2	for	for	_	_	_	_	_	_	_
3	induction	induction	_	_	_	_	_	_	_
4	of	of	_	_	_	_	_	_	_
5	apoptosis	apoptosis	_	_	_	_	_	_	_
6	was	be	_	_	_	_	_	_	_
7	markedly	markedly	_	_	_	_	_	_	_
8	increased	increase	_	_	_	_	_	_	_
9	by	by	_	_	_	_	_	_	_
10	these	these	_	_	_	_	_	_	_
11	treatments	treatment	_	_	_	_	_	_	_
12	in	in	_	_	_	_	_	_	_
13	apoptosis	apoptosis	_	_	_	_	_	_	_
14	sensitive	sensitive	_	_	_	_	_	_	_
15	cell	cell	_	_	_	_	_	_	_
16	lines	line	_	_	_	_	_	_	_
17	.	.	_	_	_	_	_	_	_

1	Moreover	moreover	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	both	both	_	_	_	_	_	_	_
4	in	in	_	_	_	_	_	_	_
5	cell	cell	_	_	_	_	_	_	_
6	lines	line	_	_	_	_	_	_	_
7	and	and	_	_	_	_	_	_	_
8	in	in	_	_	_	_	_	_	_
9	primary	primary	_	_	_	_	_	_	_
10	leukemia	leukemia	_	_	_	_	_	_	_
11	cells	cell	_	_	_	_	_	_	_
12	that	that	_	_	_	_	_	_	_
13	are	be	_	_	_	_	_	_	_
14	resistant	resistant	_	_	_	_	_	_	_
15	towards	towards	_	_	_	_	_	_	_
16	induction	induction	_	_	_	_	_	_	_
17	of	of	_	_	_	_	_	_	_
18	apoptosis	apoptosis	_	_	_	_	_	_	_
19	by	by	_	_	_	_	_	_	_
20	DILs	dil	_	_	_	_	_	_	_
21	and	and	_	_	_	_	_	_	_
22	doxorubicin	doxorubicin	_	_	_	_	_	_	_
23	,	,	_	_	_	_	_	_	_
24	antagonization	antagonization	_	_	_	_	_	_	_
25	of	of	_	_	_	_	_	_	_
26	NFkappaB	NFkappaB	_	_	_	_	_	_	_
27	activity	activity	_	_	_	_	_	_	_
28	partially	partially	_	_	_	_	_	_	_
29	restored	restore	_	_	_	_	_	_	_
30	apoptosis	apoptosis	_	_	_	_	_	_	_
31	sensitivity	sensitivity	_	_	_	_	_	_	_
32	.	.	_	_	_	_	_	_	_

1	These	these	_	_	_	_	_	_	_
2	data	datum	_	_	_	_	_	_	_
3	suggest	suggest	_	_	_	_	_	_	_
4	that	that	_	_	_	_	_	_	_
5	inhibition	inhibition	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	NFkappaB	NFkappaB	_	_	_	_	_	_	_
8	activation	activation	_	_	_	_	_	_	_
9	may	may	_	_	_	_	_	_	_
10	provide	provide	_	_	_	_	_	_	_
11	a	a	_	_	_	_	_	_	_
12	molecular	molecular	_	_	_	_	_	_	_
13	approach	approach	_	_	_	_	_	_	_
14	to	to	_	_	_	_	_	_	_
15	increase	increase	_	_	_	_	_	_	_
16	apoptosis	apoptosis	_	_	_	_	_	_	_
17	sensitivity	sensitivity	_	_	_	_	_	_	_
18	in	in	_	_	_	_	_	_	_
19	anticancer	anticancer	_	_	_	_	_	_	_
20	treatment	treatment	_	_	_	_	_	_	_
21	.	.	_	_	_	_	_	_	_

